Company Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizures; Ruzurgi for the treatment of pediatric LEMS patients; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy.
The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.
Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
| Country | United States |
| Founded | 2002 |
| IPO Date | Nov 8, 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 181 |
| CEO | Richard John Daly |
Contact Details
Address: 355 Alhambra Circle, Suite 801 Coral Gables, Florida 33134 United States | |
| Phone | 305 420 3200 |
| Website | catalystpharma.com |
Stock Details
| Ticker Symbol | CPRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001369568 |
| CUSIP Number | 14888U101 |
| ISIN Number | US14888U1016 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Richard John Daly M.B.A. | President, Chief Executive Officer and Director |
| Jeffrey Del Carmen | Executive Vice President and Chief Commercial Officer |
| Mary Coleman | Vice President and Head of Investor Relations |
| Brian Elsbernd J.D. | Chief Compliance Officer and Chief Legal Officer |
| Gregg Russo | Chief Human Resources Officer |
| Philip B. Schwartz Esq. | Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2025 | ARS | Filing |
| Apr 11, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 9, 2025 | 8-K | Current Report |
| Mar 6, 2025 | 144 | Filing |
| Mar 5, 2025 | 144 | Filing |
| Mar 3, 2025 | 144 | Filing |
| Mar 3, 2025 | 144 | Filing |
| Feb 26, 2025 | 8-K | Current Report |
| Feb 26, 2025 | 10-K | Annual Report |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |